February 23, 2023 at 7:00 AM EST AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, [...]
The Support Sight Foundation and founder Dawn Prall were so excited to be featured on the podcast Healthcare on the Horizon. In this podcast, Dawn talks about the prevalence of macular degeneration. Take a listen below! Hi everyone. [...]
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has submitted a New Drug Application (NDA) to the United States Food and Drug [...]
Modus Outcomes, a scientific research company, will be doing a global survey later this year for the MOSAIC study. The study explores people’s experiences with geographic atrophy (GA), which is also known as advanced dryage-related macular degeneration (AMD). We are [...]
"Research makes medicine" guides our mission to find a cure! We continue to fund groundbreaking research that was started many years ago by the Macula Vision Research Foundation (MVRF). Our mission to save sight for millions with MacD – is [...]
Dawn Prall and Joshua Dunaief discuss AMD Central, a new site for people living with the condition Recently, I talked to Dawn Prall, founder and executive director of The SupportSight Foundation, and Joshua L. Dunaief, Adele Niessen Professor of Ophthalmology [...]
The STEP Program™: Supporting Solutions From Patient Advocacy Organizations Patient advocacy organizations are a key source of information, empowerment, and support for patients at every step of their health care experience, helping them and their families navigate the care they need. [...]
AMDCentral.org provides access to resources for patients and caregivers in one location AMD Central is a collaboration between the American Macular Degeneration Foundation, BrightFocus Foundation, MD Support, Prevent Blindness and The SupportSight Foundation BALA CYNWYD, Penn., March 25, 2021 /PRNewswire/ -- The [...]
Bala Cynwyd, Pa. - It is estimated that 20 million Americans are now living with age-related macular degeneration (AMD) or low vision – yet, many are left in the dark about living with this devasting disease that robs precious eyesight. [...]
Novartis announced today that the US Food and Drug Administration (FDA) approved BEOVU® (brolucizumab-dbll) injection for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is caused by too much VEGF (vascular endothelial growth factor), a protein which [...]
The Support Sight Foundation is a 501(c)(3) public charity EIN# 83-1475951.The official registration and financial information may be obtained from the PA Department of State PA ID# 115901. Call 800-732-0999. Registration does not imply endorsement. All contributions are tax-deductible to the full extent of the law.
IRS regulations require us to inform you that no goods or services were provided in return for your gift. TSSF is a 501(c)(3) tax exempt organization.
We would be happy to provide you with a current audited financial report upon request. Please allow 1- 7 business days for a response.
Please contact us:
By Mail: 45 E. City Ave # 516, Bala Cynwyd, PA 19004-2621
By Phone: 888-681-8773 or 610-952-3034
By Email: info@supportsight.org
Copyright ©2023 Support Sight Foundation | All Rights Reserved
